基于MRI质子密度脂肪分数的健康体检人群中NAFLD、MAFLD与MASLD患病率随命名变化的差异
本研究纳入2020年1月至2022年11月在健康体检门诊接受肝脏MRI-PDFF的844名参与者,以MRI-PDFF≥5%定义肝脂肪变,比较NAFLD、MAFLD和MASLD的患病率及SLD亚分类。NAFLD、MAFLD和MASLD患病率分别为25.9%、29.5%和25.2%,MASLD占NAFLD患者的97.3%;MetALD亚组较MASLD组更年轻、以男性为主,且天冬氨酸氨基转移酶、γ-谷氨酰转肽酶和甘油三酯水平更高。
要点
- MRI-PDFF≥5%定义肝脂肪变时,MASLD患病率25.2%与NAFLD的25.9%相近,MASLD占NAFLD的97.3%。
- MAFLD患病率29.5%高于NAFLD和MASLD,SLD总患病率30.5%。
- MetALD亚组较MASLD组更年轻、以男性为主,AST、GGT和甘油三酯更高。
核心结论
- 以MRI-PDFF评估时NAFLD与MASLD患病率相似,MASLD占NAFLD患者的97.3%;单独的MetALD亚分类可能具有与MASLD不同的临床特征。
研究设计与样本
- 研究论文;纳入2020年1月至2022年11月在本健康体检门诊接受肝脏MRI-PDFF的844名参与者;以MRI-PDFF≥5%定义肝脂肪变,并按NAFLD、MAFLD、MASLD及SLD亚分类进行分组。
关键影像表现/征象
- 以MRI-PDFF≥5%为肝脂肪变标准,844名体检参与者中SLD总患病率为30.5%。
诊断标准与关键数值
- 肝脂肪变定义为MRI-PDFF≥5%。
- NAFLD、MAFLD和MASLD患病率分别为25.9%、29.5%和25.2%。
- SLD亚分类患病率:MASLD为25.2%,MASLD合并酒精相关性肝病(MetALD)为3.7%,酒精相关性肝病为0.1%,特定病因SLD为1.3%,隐源性SLD为0.1%。
临床应用与阅片要点
- 在健康体检人群中依据MRI-PDFF≥5%判定肝脂肪变后,可按NAFLD、MAFLD、MASLD及SLD亚分类分别统计患病率。
- MASLD占NAFLD患者的97.3%,提示两种命名下多数患者重合。
- MetALD亚组较MASLD组更年轻、以男性为主,且AST、GGT和甘油三酯水平更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: International expert panels proposed new nomenclatures, metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020 and metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, along with revised diagnostic criteria to replace non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the differences in NAFLD, MAFLD, and MASLD prevalence with changing nomenclature in a health check-up using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) to assess hepatic steatosis. We also examined the prevalence of the sub-classifications of steatotic liver disease (SLD) and the differences in characteristics among the sub-categories.
METHODS: We included 844 participants who underwent liver MRI-PDFF at our health check-up clinic between January 2020 and November 2022. Hepatic steatosis was defined as MRI-PDFF ≥ 5%. Participants were categorized according to NAFLD, MAFLD, MASLD, and sub-classifications of SLD.
RESULTS: The prevalence rates of NAFLD, MAFLD, and MASLD were 25.9%, 29.5%, and 25.2%, respectively. 30.5% of the participants was categorized as SLD. The prevalence rates of the SLD sub-categories were 25.2% for MASLD, 3.7% for MASLD and alcohol-associated liver disease (MetALD), 0.1% for alcohol-associated liver disease, 1.3% for specific etiology SLD, and 0.1% for cryptogenic SLD. Compared with patients in the MASLD group, those in the MetALD group were younger, predominantly male, and exhibited higher levels of serum aspartate aminotransferase, gamma-glutamyl transpeptidase, and triglycerides.
CONCLUSION: The prevalences of NAFLD and MASLD assessed using MRI-PDFF were similar, with MASLD accounting for 97.3% of the patients with NAFLD. The separate MetALD sub-category may have clinical characteristics that differ from those of MASLD.
引用
- Park HJ, Lee S, Lee JS, et al. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction. Abdom Radiol (NY). 2024. PMID: 38587630. doi:10.1007/s00261-024-04285-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。